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Introduction
Radioiodine (131I) has been the treatment of choice for
toxic nodular goiter, Graves’ disease and metastatic
thyroid cancer for over half a century. We have used
131I whole body scans and serum thyroglobulin
measurements to follow patients with differentiated
thyroid cancer to detect local recurrences or distant
metastases. If 131I ablation therapy for thyroid remnants
is performed after total thyroidectomy, the sensitivity
and specificity of 131I whole body scans and serum
thyroglobulin measurements will increase. Further,
131I treatment for differentiated thyroid carcinoma
with lung and bone metastases prolongs survival and
improves quality of life. However, ionizing radiation is
believed to be leukemogenic, and although uncommon,
leukemia after exposure to 131I therapy for thyroid
cancer has been reported.1–5 Many cases were of acute
myeloid leukemia, usually occurring after cumulative
dosages of more than 800 mCi, in patients older than
50 years, and with intervals of less than 12 months
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between 131I therapy.2,5 Only 9 cases of chronic myeloid
leukemia (CML) after 131I therapy for thyroid cancer
have been reported in the English medical literature.
Here, we describe an additional case of CML, which
was noted 13 years after the first dose of 131I treatment
for papillary thyroid cancer.
Case Report
In November 1987, a 12-year-old male underwent
total thyroidectomy and cervical lymph node resection
for papillary carcinoma of the right thyroid lobe with
lymph node metastasis. In July 1990, October 1991,
and August 1992, he received 131I radiotherapy (doses
of 30, 30, and 60 mCi, respectively) for avid uptake of
131I over the anterior neck region on 131I whole body
scan. Lung metastasis was suspected on the post-131I
therapy scan in August 1992, but a repeat scan in
March 1993 found complete resolution of the
pulmonary lesions. Later, because of persistent
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accumulation of 131I in the thyroid bed on subsequent
scans, he took 131I in doses of 100, 100, 100, and 150
mCi, respectively, in July 1993, September 1994,
November 1995, and April 1998. After the last 150
mCi of ablation therapy, a follow-up scan still showed
increased 131I uptake in the thyroid bed and right
pulmonary hilum (Figure 1). However, no more 131I
was given. The patient was maintained on suppressive,
exogenous thyroid hormone therapy, with the level of
thyroid stimulating hormone maintained at 0.1–0.4
+IU/mL. The total dosage of 131I was 670 mCi,
administered in 8 doses from July 1990 to April 1998.
The time intervals between 131I doses ranged from 10–
13 months.
In January 2003, when he was 27 years old, the
patient presented to our oncology ward with a
2-month history of general weakness, skin eruption,
and night sweats. Priapism had occurred weeks earlier.
The patient was first treated at Da-Lin Tzu-Chi
Hospital, where laboratory examination revealed a
white blood cell count of 56,920/mm3, with 32%
neutrophils, 13% bands, 11% monocytes, 10%
lymphocytes, 9% basophils, 8% metamyelocytes, 5%
promyelocytes, 3% blast cells, 2% myelocytes, and 2%
eosinophils. Hemoglobin was 10 g/dL and platelet
count was 826,000/mm3. Leukocyte alkaline
phosphatase score was 0, and lactate dehydrogenase
level was 364 U/L. Bone marrow aspiration and
biopsy showed marked hypercellularity. The
Philadelphia (Ph) chromosome was present, and
repeated bone marrow examination and chromosome
analysis in our oncology ward confirmed the diagnosis
of Ph-positive CML (Figure 2).
The patient had no family history of leukemia or
thyroid disease, and he had not received external
radiotherapy in the past. He was treated with
hydroxyurea and prepared for allogeneic stem cell
transplantation from his human leukocyte antigen
(HLA)-identical sibling.
Discussion
Leukemia as a complication of 131I therapy is rare, but
there is still concern about the possible carcinogenic
effect of 131I. For example, in 1963, Haynie and
Beierwaltes6 reported transient, dose-dependent,
hematopoietic changes in patients receiving 131I for
thyroid cancer, and in 1986, Van Nostrand et al7
found transient bone marrow suppression in post-131I
therapy patients; some of these patients still had reduced
baseline blood counts 1 year after 131I therapy.
The development of leukemia in patients treated
for thyrotoxicosis or thyroid carcinoma has also been
reported. Pochin,1 in reviewing 60,000 cases of
thyrotoxicosis treated with 131I, found 17 cases of
leukemia, of which 13 were acute, 1 was subacute, and
3 were chronic monocytic. The same author described
4 cases of acute leukemia in 175 patients treated with
131I for thyroid cancer, thus giving a leukemia incidence
of 2.3%, compared with an expected incidence of 0.4%
in the general population.2 Saenger et al3 reported a
mildly increased risk of leukemia in hyperthyroid
patients treated with radioiodine (n = 22,000) versus
surgery (n = 14,000) (p < 0.05); these authors also
suggested an association between hyperthyroidism
Figure 1. 131I whole body scan (9 October 1988) showing persistent
remnants in the thyroid bed and possible right hilar lymph node
metastasis. In the lower figure, markers are superimposed on the
scan. SN = sternal notch; XP = xyphoid process; ±A= remnant
thyroid tissue; A = possible right hilar lymph node metastasis.
Figure 2. Karyotype of bone marrow cells showing the translocation
t(9;22)(q34;q11.2).
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and leukemia, but of unknown mechanism. Indeed,
the observed mortality from leukemia was 50% greater
in hyperthyroid patients than in the US population as
a whole.3
Among the reported cases of leukemia as a
complication of 131I therapy, CML has been docu-
mented much less frequently than acute leukemia.
Apart from the present case, only 9 other cases of CML
after 131I therapy for carcinoma of the thyroid have
been reported (Table 1).4,8–14 Most CML patients have
a unique genetic translocation between chromosomes
9 and 22 in myeloid cells: the abl cellular oncogene is
transferred from chromosome 9 to the bcr gene of
chromosome 22. Ionizing radiation, including 131I,
is known to be markedly effective in producing
chromosome translocations, thus providing a probable
mechanism for the development of leukemia after 131I
treatment.
In the abovementioned 10 cases of CML, 2 patients
had received high-voltage radiotherapy, which could
have been an important factor in the development of
secondary leukemia. The mean total dosage of 131I
administered to the 10 CML patients was 329.6 mCi
(range, 30–850 mCi), the age range was 27–76 years,
and the latent period between 131I exposure and the
detection of CML ranged from 10 months to 13 years.
Among the 10 cases, our patient was the youngest and
had the longest latent period. Six patients were diagnosed
4–7 years after their first radiation exposure; thus, the
median latency period seemed shorter than that of 11
years (range, 2–25 years) in a group of Japanese atomic
bomb survivors who developed CML.15
Japanese atomic bomb survivors have an increased
estimated risk of leukemia. Nonetheless, it is unclear
whether radiation exposure over time results in a lower
leukemia risk than acute exposure to the same total
dosage of radiation.15 The Chernobyl accident led to
the release of a considerable amount of various iodine
radioisotopes, including 131I, into the atmosphere, and
an increased incidence of thyroid cancer has been
observed in children living in the heavily contaminated
areas; so far, however, the incidence of other malig-
nancies, including leukemia, does not seem to have
changed markedly.16
In 2 retrospective studies, Brincker et al4 and
Edmonds and Smith5 found a significant increase in
the incidence of leukemia after 131I therapy in 194
and 248 patients, respectively, with thyroid cancer.
However, 3 large cohort studies in recent years are
reassuring in that no instances of CML were ob-
served:17–19 a Swedish study in 1,955 2-year survivors
who were followed-up for a mean of 17 years, and of
whom 834 were treated with 131I, detected only an
increased risk of chronic lymphocytic leukemia, a
malignancy that has not so far been associated with
radiation;17 an Italian study in 941 3-year survivors
who were followed-up for a mean of 8 years, and of
whom 730 were treated with 131I, found no cases of
leukemia;18 and a French study in 1,771 2-year
survivors with thyroid cancer who were followed-up
for a mean of 10 years, and of whom 1,491 were
treated with 131I, reported no secondary leukemias.19
These inconsistent results may stem from the different
dosage ranges and follow-up periods employed in the
various trials.
In conclusion, only a small proportion of patients
with thyroid cancer treated with radioiodine have
developed leukemia, and it is not absolutely certain
that leukemia was caused directly by 131I. However,
long-term follow-up in 131I-treated patients with thyroid
cancer should be emphasized, and leukocytosis in such
patients should raise the suspicion of CML.
Table 1. Review of patients who developed chronic myeloid leukemia after 131I treatment for thyroid cancer
Authors Age (yr)/Gender 131 I dose (mCi)
Time interval from
External radiation
first 131I dose
Ozarda et al (1961)8 75/F 347 4.7 yr –
Brincker et al (1973)4 76/F 600 10 mo –
Bundi et al (1977)9 55/M 850 11 yr +
Torng et al (1984)10 37/M 100 65 mo –
Walgraeve et al (1991)11 43/M 30 5 yr –
Advani & Hege (1992)12 Middle-aged/F 103 7 yr –
Shimon et al (1995)13 35/M 56 4 yr –
51/M 130 10 yr –
Alfiar et al (1997)14 57/F 410 6 yr +
Wang et al (present case) 27/M 670 13 yr –
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